• SyncroPatch 384/768PE

    世界最速のオートパッチ
  • SyncroPatch 384/768PE

    384ch同時測定 => 768chへアップグレード可能
  • SyncroPatch 384/768PE

    ギガシールによるHTS
  • SyncroPatch 384/768PE

    細胞内灌流中もデータ取得可能
  • SyncroPatch 384/768PE

    最先端技術によるアッセイ柔軟性

SyncroPatch 384/768PE - Patch clamp meets HTS

SyncroPatch 384PE (768PEへアップグレード可能) は384(768)細胞同時測定が可能なハイスループットのパッチクランプ装置です。SyncroPatch 384/768PEはオートパッチ市場において、ギガシールのデータ品質を誇る最速のパッチクランプ装置です。 SyncroPatch 384/768PE は以下のような優位性を有しています:

  • ギガシール記録
  • ホウケイ酸ガラス製のチップ基材(化合物吸着を低減)
  • >85 % 以上の成功率をルーチンに達成可能
  • 細胞内 & 細胞外液の溶液交換
  • 温度コントロール
  • ボルテージ & カレントクランプ
  • ホールセル & 穿孔パッチ
  • シングル & マルチホールチップ(社内製造)
  • シリーズ抵抗補償
  • 化合物暴露 & wash回数の制限なし
  • 少化合物量
  • 電位依存性 & リガンド依存性チャネル (電位固定は常時)
  • 細胞株 & 幹細胞
  • CiPA用バリデート済システム
  • 強力な解析ソフト(自動IVプロット & IC50算出)

SyncroPatch 384/768PE は、イオンチャネル創薬における一次スクリーニングと二次スクリーニングのギャップを埋める世界初のハイクオリティーなオートパッチクランプ装置となります。 創薬プロセスに全自動の化合物スクリーニングをシームレスに統合できるように設計されており、最新の384chリキッドハンドリングロボット Biomek FXP 384 chのパッチクランプアンプを搭載するモジュールデザインとなっています。

ハードウェアとソフトウェアは真のイオンチャネルHTSにおいて最高のパフォーマンスを提供するために、創薬開発のリーディングカンパニーで完全にバリデート済みです。最大でPE-モジュールを2台まで1台の分注機に統合でき、768ch独立アンプにより、768ウェルからの同時測定を可能にします。もちろん、導入後も容易に384chから768chへのアップグレードが可能です。

1モジュールで最大 20,000 データポイントのスループットにより(2モジュール搭載で40,000データポイント)、オートパッチ市場で最も効率的に高品質なパッチクランプ記録を取得できるプラットフォームとなります。この比類なき生産性は、384ウェルの完全な同時測定、384ch分注ヘッドだけではなく、極めて効率的な制御&解析ソフトウェアが貢献しています。

詳細情報:

特徴&仕様

SyncroPatch 384/768PE 技術仕様

PE Technical specification


SyncroPatch 384/768PE: システム構成例

SyncroPatch 384/768PE 主なシステム構成品:

  • Biomek FXP (384ヘッド, グリッパー装備)
  • Patch Engine モジュール×1台,384chアンプ×1台 (384PE*)
    Patch Engine モジュール×2台,384chアンプ×2台 (768PE*)
    * 384PEは384ウェル同時測定,786PEは768ウェル同時測定可能
  • ソフトウェアパッケージ(PatchControl 384, DataControl 384)
  • 温調付きセルホテル
  • バーコードリーダー
  • スターターキット
  • チェリーピッキング用8chピペッター(span-8, ハイブリッドモデル用オプション)

ソフトウェア

PatchControl 384

PatchControl 394PE

PatchControl 384ソフトウェアは、電位プロトコールや実験パラメータを直感的かつ迅速、容易にセットアップできる非常に強力なGUIです。シール抵抗、シリーズ抵抗、膜容量などのユーザー指定のQC基準に基づき、測定ウェルは可視化、色分けされます。また、マウスのワンクリックで、IV曲線や用量依存性曲線などのオンライン解析結果に瞬時にアクセスできます。



DataControl 384: 解析ソフトウェア

DataControl 384ソフトウェアは、ユーザー定義の解析テンプレートを使用してPatchControl 384で記録したデータの可視化及び解析を行います。解析結果 ( IC50, EC50, IV特性の自動計算、プロッティング)、 化合物情報、QCパラメーターはユーザー定義の雛形でエクスポートされ、PDFレポートの自動作成、データベースへの統合準備なども行われます。これらの解析プロセスは、簡便かつ迅速、直感的に実施できます。

消耗品

NPC-384 パッチクランプチップ

NPC 384

NPC-384チップは、SyncroPatch 384/768PE専用に開発された革新的なNanion Technologiesの自社製品です。全てのチップは、厳格なQC管理の下でナニオンのドイツ本社にて製造され、ドイツミュンヘンから世界のユーザーへ発送されます。細胞のサイズやアプリケーションに合わせて、各種のNPC-384チップから最適なチップお選びいただけます。


Material
パッチ形成用のアパーチャを有するホウケイ酸ガラスのスライドが、細胞及び細胞外液や薬液を適用する384ウェルプレートに統合されています。さらに、実験中に細胞内液の灌流を容易に行うことができます。
特徴

各NPC-384チップは、384 個の測定チャンバーで構成されています。 384ウェルを全て同時に使用することもできるほか、2カラム(32ウェル)毎に使用することも可能です。SyncroPatch 384PEでは1チップ(384ウェル)の測定、SyncroPatch 768PEでは、2チップ(768ウェル)の同時測定が可能です。もちろん、ユーザー不在での全自動稼働が可能です。 また、細胞内液、細胞外液や薬液の適用/交換回数に制限はありません。


NPC-384 パッチクランプチップ 製品ラインナップ
  • 製品名:仕様 (製品コード)
  • NPC-384 パッチクランプチップ 1x Medium   :1ホール/ウェル、中抵抗 (製品コード 221102)
  • NPC-384 パッチクランプチップ 1x Medium plus:1ホール/ウェル、中~高抵抗 (製品コード 221104)
  • NPC-384 パッチクランプチップ 4x Medium   :4ホール/ウェル、中抵抗 (製品コード 221402)
  • NPC-384 パッチクランプチップ 8x Medium   :8ホール/ウェル、中抵抗 (製品コード 221802)
  • NPC-384 パッチクランプチップ 9x Medium   :9ホール/ウェル、中抵抗 (製品コード 221902)
  • NPC-384 パッチクランプチップ 1x High    :1ホール/ウェル、高抵抗 (製品コード 221101)
  • NPC-384 パッチクランプチップ 4x High    :4ホール/ウェル、高抵抗 (製品コード 221401)
  • NPC-384 パッチクランプチップ 8x High    :8ホール/ウェル、高抵抗 (製品コード 221801)
  • NPC-384 パッチクランプチップ 9x High    :9ホール/ウェル、高抵抗 (製品コード 221901)
  • NPC-384 パッチクランプチップ 1x Low    :1ホール/ウェル、低抵抗 (製品コード 221103)
  • NPC-384 パッチクランプチップ 4x Low    :4ホール/ウェル、低抵抗 (製品コード 221403)
  • 試薬

    SyncroPatch 384/ 768PE 試薬

    SyncroPatch 384/ 768PEの実験用バッファー、パッチクランプ溶液はパートナー会社で製造後、ドイツのナニオン本社ラボで厳格な品質チェックを行い、ドイツミュンヘンから世界のユーザーへ発送されます。


    試薬ラインナップ
    • SyncroPatch細胞外液, 500 mL スタンダード:(製品コード 083001)
    • SyncroPatch細胞内液, 500 mL 特注:組成はお打合せ (製品コード 083002)
    • SyncroPatch試薬キット 10 L スタンダード:4x 500 mL 細胞内液スタンダード(組成は標準組成から選択), 12 x 500 mL 細胞外液スタンダード (製品コード 082102)
    • SyncroPatch試薬キット 2.5 L スタンダード: 1x 500 mL 細胞内液スタンダード (組成は標準組成から選択); 4 x 500 mL 細胞外液スタンダード (製品コード 082101)

    データ&アプリケーションノート

    AMPA Receptor (GluA2) - Pharmacology

    icon sp96   GluR2 PE Data PharmacologySyncroPatch 384PE data and applications:
    Cells were kindly provided by SB Drug Discovery.

    The AMPA receptor (GluA2) was analyzed using different positive and negative allosteric modulators (CNQX, LY404187, LY395153, CP465022, Cyclothiazide). After activating the receptor by application of Glutamate, the modulating compound plus glutamate was applied afterwards. Measured on the SyncroPatch 384PE the whole cell patch methodology and multi-hole chips were used.
    The lower images on the left hand side are displaying a screenshot of a current after application of the positive modulator LY404187. The EC50 was determined as 379 nM.

    AMPA Receptor (GluA2) - Activation by Glutamate

    icon sp96   GluR2 PE DataSyncroPatch 384PE data and applications:
    Cells were kindly provided by SB Drug Discovery.

    The AMPA receptor (GluA2) was activated using different concentrations of glutamate (1 µM - 100 µM). Measured on the SyncroPatch 384PE the whole cell patch methodology and multi-hole chips were used.
    The lower two images are displaying screenshots of single cell currents after repetitive glutamate applications:
    Left: The same concentration of Glutamate was applied three times.
    Right: Four different Glutamate concentrations were applied in a cumulative manner.

    AMPA Receptor (GluA2) - Cumulative Concentration Response

    icon sp96   GluA2 GluCRC SP384PE SBSyncroPatch 384PE data and applications:
    Cells were kindly provided by SB Drug Discovery.

    The AMPA receptor (GluA2)was activated by increasing concentrations of glutamate on the SyncroPatch 384PE. L-glutamate was applied for approximately 500 ms in increasing concentrations (A) and a cumulative concentration response curve for glutamate was constructed for 222 wells (C).
    The online analysis values peak amplitude and area under the curve (AUC) are shown versus time in Panel B. The fast activation of GluA2 could be captured at higher concentrations (inset; 1 mM).

    NaV1.8 - State Dependent Inhibition

    icon sp96   PE NaV1.8 State dep InhibitionSyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    The state dependent inhibition of Tetracaine on NaV1.8 currents were investigated. Measured on the SyncroPatch 384PE the perforated cell patch methodology (Escin) and multi-hole chips were used and compared to single-whole chips. Using a state dependant pulse protocol, the IC50 value determined from the first pulse (C1) was calculated as 54.3 µM (Hill coefficient = 1.50), and from the second pulse (C2) as 1.27 µM (Hill coefficient = 0.62). 

     

    NaV1.7 - Frequency Dependent Inhibition

    icon sp96   PE NaV1.7 TetracaineSyncroPatch 384PE data and applications:
    Cells were kindly provided by Anaxon.

    The frequency dependent inhibition of Tetracaine (5 µM, 15 µM and 50 µM) on NaV1.7 currents were investigated. Measured on the SyncroPatch 384PE the whole cell patch methodology and single-hole chips were used. The IC50 value determined from the first pulse of the pulse train was calculated as 41.8 µM, from the second pulse as 9.9 µM and from the 10th pulse as 3.0 µM. 

     

    NaV1.7 - Pharmacology of Lidocaine

    icon sp96   PE NaV1.7 LidocaineSyncroPatch 384PE data and applications:
    Cells were kindly provided by Anaxon.

    The effect of different concentrations of Lidocaine on NaV1.7 currents were investigated. Measured on the SyncroPatch 384PE the whole cell patch methodology and single-hole chips were used. The success rate of > 90% for cells which had a seal resistance > 500 MΩ was determined. A value of 0.79 was calculated for the z-factor (characterization of HTS screening assay quality).

    NaV1.5 - Late Current Analysis using the CiPA Protocol

    CiPA PE NaV1 5 Pharmacology late currenticon sp96   SyncroPatch 384/768 PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing NaV1.5 current traces in response to the CiPA voltage step protocol, measured on the SyncroPatch 384PE using whole cell patch clamp methodology and single-hole chips. The NaV1.5 late current was activated by the application of 60 nM ATX-II. The IC50 value of Ranolazine of the late Sodium current current was determined as 40.4 µM.

     

    hERG - Pharmacology at Physiological Temperature using the CiPA Protocol

    CiPA PE hERG Pharmacology 35DegreeCelsiumicon sp96   SyncroPatch 384/768 PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol at 35 degree Celsius. Measured on the SyncroPatch 384PE using perforated patch clamp methodology (Escin) and multi-hole chips (4 holes per well). The IC50 value of Erythromycin of the peak current was determined as 60.5 µM. 

     

    KV4.3 - Pharmacology of Metropolol Tartrate, using the CiPA Protocol

    CiPA PE KV4.3 2icon sp96   SyncroPatch 384/768 PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV4.3 current traces in response to the CiPA voltage step protocol, measured on the SyncroPatch 384PE using the whole cell patch methodology and single-hole chips. The IC50 value of Metropolol Tartrate was determined as 128 µM.

     

     

    CaV1.2 - Pharmacology of Nifedipine, using the CiPA protocol

    icon sp96   CiPA PE CaV1 2 2SyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hCaV1.2/β2/α2δ1 current traces in response to the CiPA voltage step protocol and the corresponing current-voltage relationship plot. Measured on the SyncroPatch 384PE using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 94%. The IC50 value of Nifedipine was determined as 106 nM.

     

    hERG - Pharmacology using the CiPA Protocol

    CiPA PE hERG Pharmacologyicon sp96   SyncroPatch 384/768 PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE using whole cell patch clamp methodology and multi-hole chips (4 holes per well). The IC50 value of the following compounds of the peak current was determined as 4.18 µM for Diltiazem, 37.4 nM for Terfenadine, 971 nM for Quinidine, 63 µM for Mexiletine, 431 nM for Verapamil and 4.54 µM for Ranolazine. 

    hERG - recordings with great stability using the CiPA step ramp protocol

    CiPA PE hERG Pharmacology Stabilityicon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hERG current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE using perforated patch clamp methodology (Escin) and multi-hole chips (4 holes per well). 

    Cardiac Ion Channels - Pharmacology of Sotalol

    CiPA PE CE Pharmacology SotalolIcon CE    CardioExcyte 96 and   icon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River and Cellular Dynamics.

    The image on the left hand side displays the results of the blocking effect of Sotalol on hERG. The result is in good agreement with manual patch clamp data (Crumb et al., 2016). The compound induced arrhythmia when iPSC-CM were exposed to a minimum concentration of 10 µM. Arrhytmic events were both detected in field potential recordings as well as in the impedance based contractility measurements.

    KV4.3 - Pharmacology of Quinidine

    CiPA PE Kv4 3icon sp96   SyncroPatch 384/768 PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV4.3 current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE using the whole cell patch methodology and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was  95.3%. The IC50 value of Quinidine was determined as 21.2 µM (Literature: 79.3 µM, Crumb et al., J Pharmacol Toxicol Methods. 2016).

    Kir2.1 - Pharmacology of Barium

    CiPA PE Kir2 1icon sp96   SyncroPatch 384/768 PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing Kir2.1 current traces in response to a voltage step protocol. Measured on the SyncroPatch 384PE using the whole cell patch methodology and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was  93%. The IC50 value of Barium was determined as 6.38 µM (Literature: 16.2 µM, Schram et al. Cardiovasc Res. 2003).

    KCa3.1 (SK4) - Activation by Perfusion of free internal Calcium

    180209 Data PE SK4icon sp96   SyncroPatch 384/768 PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software are showing KCa3.1 raw traces and according time plots (online analysis) to a voltage ramp from -120 mV to + 60 mV over 200 ms. The application of internal Ca2+ is indicated by the yellow bar. The current increased upon application of internal Ca2+ reaching a peak within 1-2 min after the start of the perfusion. Five minutes of stable KCa3.1 current was recorded prior the channel was inhibited by cumulative additions of external Ba2+; first partly (1 mM Ba2+) and then completely (5 mM Ba2+). The recording was performed with perfectly high success rates in whole cell configuration on a multi hole chip (4 holes per well) using the SyncroPatch 384PE.

    NaV1.9 - Pharmacology

    NaV1.9 Dataset PE 1icon sp96   SyncroPatch 384/768 PE data and applications:
    Cells were kindly provided by Icagen.

    Screenshots of the PatchControl 384 software showing hNaV1.9 current traces in response to a voltage step protocol. Measured on the SyncroPatch 384PE using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was  86%. NaV1.9 is TTX insensitive. The IC50 value of lidocaine of the peak current was determined as 350 µM (Literature: 356 µM), the IC50 value of tetracaine of the peak current was determined as 12.5 µM (Literature: 32 µM).

    NaV1.7 - Accurate Voltage Clamp

    SyncroPatch 384PE Nav17 CHO Anaxon 384 raw IV 2

     icon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by Anaxon AG.

    CHO cells expressing NaV1.7 were used on the SyncroPatch 384PE with a success rate of > 90% for cells which have a seal resistance > 500 MΩ (see inset). A screenshot of the PatchControl 384 software showing current traces in response to a voltage step protocol and the corresponding current-voltage plot.

    GABAA Receptor (a1b3g2) - Antagonists

    GABAa1 Antagonists

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Pharmacology on GABAA α1β3γ2 as recorded on a multihole (4x) plate. Mean concentration response curves for Bicuculline, IC50 = 470 nM (n = 14); for a5IA IC50 = 461.19 pM (n = 9), maximum block was 29% at 100 nM; for FG7142 IC50= 54.52 nM (n = 15), maximum block was 58% at 10 μM; for MRK016 maximum current inhibition was 44.8% at 1 uM, IC50= 5.98 nM (n = 11). 

    GABAA Receptor (a1b3g2) - Bicuculline Dose Response

    GABAa1 Bicuc DR vert

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Pharmacology on GABAA α1β3γ2 as recorded on a multihole (4x) plate. Raw data traces of one exemplary recording using control solution (A) and increasing Bicuculline concentrations and a subsequent  washout (B). Cells were held at a constant holding potential of -70 mV and GABA was applied for approximately 2 s. After 3 control applications of 3 μM GABA, increasing concentrations of inhibitors were applied. Cells were preincubated with antagonists before co-applicaiton with GABA. 

    GABAA Receptor (a1b3g2) - Success Rates

    Seal Stat GABAa1

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Statistic of hGABAA a1b3g2 cells recorded on one NPC-96 1-hole (1x) patch clamp chip. Cslow = 18.8 ±1.6 (n=32), Rs = 8.6 ± 1.5 (n=32). 41.66 % of the cells on one NPC-96 chip (total n=96) had seal resistance > 1 GOhm at the beginning and at the end of experiment. 63.4 % of the cells had a seal resistance above 500 MOhm, which remained stable throughout the experiment.

     

     

    GABAA Receptor (a5b3g2) - Antagonists

    GABAa5 Antagonists small

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Mean concentration response curves for Bicuculline, IC50 = 327 nM (n = 14); for a5IA IC50 = 933 pM (n = 11),  maximum block was 45% at 100 nM; for FG7142 IC50= 2.5 mM (n = 9), maximum block was 64.3% at 10 μM; for MRK016 maximum current inhibition was 52% at 1uM, IC50= 1.02 nM (n = 15).

    GABAA Receptor (a5b3g2) - Dose Response

    GABAa5 ver

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Pharmacology on GABAA α5β3γ2 as recorded on the SyncroPatch96. Raw data traces of one exemplary cell using increasing GABA concentrations (A) or increasing Bicuculline concentrations and a subsequent washout (B).

     

     

     

    GABAA Receptor (a5b3g2) - Success Rates

    Bar Seal cm Rs GABAa5AppNote

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Statistic of hGABAA α5β3γ2 cells recorded on one NPC-96 patch clamp chip. Cslow = 26.2 ±1.8 (n=32), Rs = 4.1 ± 0.2 (n=32). 53 % of the cells on one NPC-96 chip (total n=96) had seal resistance > 1 Giga Ohm at the beginning, 47 % at the end of experiment. 76 % of cells reached a seal resistance above 500 MΩ, which remained constant throughout the experiment.

     

     

     

    NaV1.8 - Block by Tetracaine

    Tet traces Conc responseicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    A Raw traces from an exemplar cell recorded on the SyncroPatch 96 showing inhibition of current by increasing concentrations of tetracaine. Shown are current responses to a single step protocol to 20 mV for 25 ms from a holding potential of -120 mV.
    B Average concentration response curve for tetracaine, IC50 = 71 ± 5 μM (n = 40).

    NaV1.8 - Block by Lidocaine

    Lido traces ConcResponseicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    A Raw traces from an exemplar cell recorded on the SyncroPatch 96 showing inhibition of current by increasing concentrations of lidocaine. Shown are current responses to a single step protocol to 20 mV for 25 ms from a holding potential of -120 mV.
    B Average concentration response curve for lidocaine, IC50 = 178 ± 11 μM (n = 35).

    NaV1.8 - I/V Characteristics

    ND723 Nav18 Syncro IV Figureicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications: 

    The ND7-23 cells were kindly provided by Millipore.

    A Raw traces from an exemplar cell recorded on the SyncroPatch 96. Shown are current responses to increasing voltage steps from -60 to +60 mV.
    B Average current-voltage plot, Vhalf of activation was 12 mV (n = 32).
    C Average inactivation plot, Vhalf of inactivation was -27 mV (n = 32). Nav1.8 currents started to activate at about -30 mV, peak response was elicited between 20 and 30 mV and Vhalf of activation was 12 mV. The Vhalf of inactivation was -27 mV in good agreement with the literature.

    NaV1.7 - Success Rate & Access Resistance

    SuccessRate Nav17 Rs Cm Syncroicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    The cells were kindly supplied by Millipore.

    A Success rate (seal resistance) of ND7-23 cells on the SyncroPatch 96. Shown is a bar graph of seal resistances on the SyncroPatch 96 at the start (blue) and end (grey) of the experiment.
    B Bar graph of cell capacitance (Cslow) of ND7-23 cells. Mean Cslow = 19.9 ± 0.8 pF (n = 75 ). 
    C Bar graph of series resistance (Rs) values for ND7-23 cells on the SyncroPatch 96. Mean Rs = 9.1 ± 1.3 MΩ (n = 75).

    NaV1.8 - Success Rate & Access Resistance

    SuccessRate Seal cm Rs ND723 Syncroicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    The cells were kindly supplied by Millipore.

    A Success rate (seal resistance) of ND7-23 cells on the SyncroPatch 96. Shown is a bar graph of seal resistances on the SyncroPatch 96 at the start (blue) and end (grey) of the experiment.
    B Bar graph of cell capacitance (Cslow) of ND7-23 cells. Mean Cslow = 22.6 ± 0.8 pF (n = 88 ).
    C Bar graph of series resistance (Rs) values for ND7-23 cells on the SyncroPatch 96. Mean Rs = 7.1 ± 0.4 MΩ (n = 88). 

     

    TRPV1 - Activation by Internal Application of Capsaicin

    0TRPV1 Internal Acticon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    The SyncroPatch 96 allows continues recording during the application of compounds from the intracellular side. Here, TRPV1 channels were activated by the internal application of capsaicin.

       

     

     

     

    NaV1.5 - Analyzing iPSC-derived Cardiomyocytes

    0NavLidocaineScreenicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly supplied by Cellular Dynamics.

    Inhibition of NaV1.5 currents in stem cell-derived cardiomyocytes (iCells) by lidocaine. Lidocaine concentrations: 6 µM, 62 µM and 620 µM. The obatined  IC50 -value was 14 µM.

     

    Acetylcholine Receptor Alpha 7 - Dose Response Curve

    AChRCRCicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Galantos Pharma GmbH.

    Increasing acetylcholine concentrations (30 µM, 100 µM and 300 µM) were added to the same cell using a stacked applications protocol. 

     

    NaV1.5 - Blind Study using an Inactivation Protocol

    NaInactivation

    icon sp96   SyncroPatch data (a predecessor model of SyncroPatch 384PE) and applications:

    22 selected compounds were tested in a blind study on the SyncroPatch 96 using HEK 293 cells expressing hNav1.5 ion channels. The IC50-values were compared to manual patch clamp measurements, performed at the customer site.

    NaV1.5 - Lidocaine Dose Response

    NaLidocaine

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Cytomyx Millipore

    Timecourse of the NaV1.5 peak currents in response to exposure to different lidocaine concentrations (0 μM, 1 μM, 10 μM, 100 μM, 0 μM). Time points at which the external solution was exchanged is marked by the red lines.

    NaV1.5 - Inactivation Protocol

    NaInactivation

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Cytomyx Millipore.

    Shown are raw current responses of HEK293 cells expressing hNaV1.5 to a double (inactivation) pulse protocol.

     

    Erythrocytes - Analyzing Primary Cells

    Erysicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Dr. Andrea Brüggemann.

    Shown is a current recording from an erythrocytes as a response to a voltage ramp from -100 mV to +100 mV aquired on the SyncroPatch 96. The increase in current was induced by a reduction in osmoliarity.

     

    NaV1.8 - Automated Analysis

    DC96 overview CRCResults Nav18icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by EMD Millipore.

    With the SyncroPatch Analysis Tool - DataControl96, IC50 plots are easily generated, displayed, averaged, evaluated, and modified.
    Here, Lidocaine concentration response curves (CRC) of rNaV1.8 expressing ND7-23 cells are shown.

    KV1.3 - Internal Perfusion

    p41 1 IntPerficon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    The SyncroPatch 96 supports internal perfusion allowing internal administration of compounds, second messengers and metabolites. Here, KV1.3 currents, endogenously expressed in Jurkat cells, were blocked by the internal administration of Cs+ followed by washout with Cs+-free internal solution.

    NMDA NR1/NR2A - Activation and Modulation

    NMDA 384well view

    icon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by B'Sys.

    Here, activation and modulation of the NR1/NR2A subunit containing NMDA receptors are shown. Currents were evoked by application of 10 µM Glutamate in the presence of 10 µM Glycine.

    Application of the neurosteroid Pregnenolone sulfate (PS) potentiates the current response induced by Glutamate. The potency of PS was analysed in a single-point screen. The EC50 of PS (39.6 µM), comprising 74% of the cells is nicely corresponding to litereature values (Irwin, et al. Neurosci. Lett. 1992)

    Glycine Receptor (GlyRa1) - Reproducible Current Recordings

    Glycine 384 raw OA reproducibleicon sp96   SyncroPatch 384PE data and applications:

    Glycine-mediated current traces and corresponding time plots from 384 simultaneously recorded HEK cells are shown. Multiple additions of 50 µM Glycine produce very robust current responses with similar peaks, providing best conditions for cumulative pharmacology on one cell.

    KV1.3 - Pharmacology with High Success Rate

    Kv13 384 raw onl norm Quini 2icon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by Evotec.

    Shown are screenshots of a pharmacology experiment performed with the SyncroPatch 384PE. Recordings from 384 KV1.3 expressing CHO cells were performed simultaneously. Original current traces and the peak current over time are displayed. Data are analysed with DataControl384 full analysis tool. With just a few mouse-clicks normalized concentration response curves can be generated. Here, normalized response and the IC50 of Quinidine is shown. Darkening shades of blue indicate increasing compound concentration.

    hERG - Stable Recordings with Accurate Pharmacology

    Syncro hERG 2icon sp96   SyncroPatch 384PE data and applications: 
    Cells were kindly provided by Charles River Laboratories.

    Current-voltage relationship of hERG (Kv11.1) expressed in HEK293 is shown along with pharmacology of 4 hERG-active compounds. The current-voltage relationships for all 384 wells (top) using perforated patch (Escin) and multi-hole chips (4 holes per well) are shown. In all 384 wells, a hERG-mediated current was observed with peak amplitude >700 pA at -20 mV. Using a pharmacology voltage protocol, experiments were stable lasting over 20 minutes. Concentration response curves for astemizole, pimozide, cisapride and terfenadine revealed IC50 values consistent with those found in the literature. 

    AMPA Receptor (GluA2) - Current Traces

    icon sp96   SyncroPatch 384PE data and applications:
    Cells were kindly provided by University of Sussex.

    Using a stacked solutions approach and a fast pipetting speed shortens the solution exchange rate and minimizes the ligand exposure time. This procedure allows for reproducible recordings of fast desensitizing ligand-gated receptors such as glutamate receptors.
    Here, repetitive activation of GluA2 receptors is shown. Receptors were activated with 100 µM Na-Glutamate for 3 times resulting in inward currents of similar peak amplitudes (A and B). The current onset time was approximately 10 ms (D). Panel C displays an example of a cumulative concentration response curve for Na-Glutamate (in mM: 0.1, 0.3 and 1).

    TRPV1 - Application of Capsaicin

    TRPV1 bea verzerrticon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    Using the SyncroPatch 96 CHO cells expressing TRPV1 were subjected to a voltage ramp (-100 mV to +100 mV) in the presence and absence (control) of 2 μM capsaicin. As shown in the exemplar traces, inward and outward currents increase upon capsaicin addition.

    GABAA Receptor - Modulator Diazepam

    Diazepam

     icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    Shown is a raw current response of a HEK293 cell expressing GABAA receptors to initial exposure to GABA, followed by joint exposure to GABA and diazepam (as indicated). Solutions were  stacked (layered) in the pipette to achieve brief exposure times.

    Acetylcholine Receptor Alpha 3 Beta 4 - Activation

    a3b4

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    Shown is a raw current response of a HEK293 cell expressing AChR (α3β4) to exposure to 300 μM nicotine. Solutions were  stacked (layered) in the pipette to achieve brief exposure times.

     

    GABAA Receptor (a1b2g2) - On-set of response

    Gaba and close up bea

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    With the SyncroPatch 96 currents can be recorded continuously during compound application. This, in conjunction with a solution exchange time of about 100 ms, makes the SyncroPatch 96 an excellent tool for investigations of ligand gated ion channels. In the data example, 10 μM GABA was added to a HEK293 cell expressing GABAA (α1β2γ2) receptors. The boxed trace shows a close up of the GABA-response.

    NaV1.5 - Current Voltage Relationship

    NaStrom IV

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Millipore.

    Borosilicate glass chips are used as the patch clamp substrate, ensuring excellent voltage clamp of the cell membrane and high quality seals. Voltage gated channels such as hNaV1.5 (HEK293) have been used to validate the system. This data example shows the I/V characteristics and the corresponding raw current traces of a single cell from a recording on the SyncroPatch 96.

     

     

    CaV1.2 - Current Voltage Relationship

    Cav12 IV

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:

    Shown are raw current traces (top) and the constructed peak current-voltage relationship (bottom) of CaV1.2 (HEK293) recorded on the SyncroPatch 96.

     

     

     

     

     

    hERG - Current Voltage Relationship

    HergIV No and with Leak

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications:
    Cells were kindly provided by Cytomyx Millipore.

    Borosilicate glass chips are used as the patch clamp substrate, ensuring excellent voltage control of the cell membrane and high quality seals. Voltage gated channels such as hERG (expressed in HEK293) have been used to validate the system. These traces show the raw current responses of a single cell to a hERG IV pulse protocol. The data were recorded on the SyncroPatch 96. In the upper screenshot raw current traces are shown. In the lower one the same current traces after leak subtraction are shown.

     

     

    KV7.1 (KVLQT) - Dose-response curve

    icon sp96   170922 KV7.1 Data SyncroPatch384PESyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV7.1/KCNE (KVLQT/minK) current traces in response to a voltage step protocol and the corresponing current-voltage relationship plot. Using the perforated patch methodology (Escin) in combination with multi-hole chips (4 holes per well), stably transfected cells were measured on the SyncroPatch 384PE. The IC50 value of Chromanol 293B was determined as 3.82 µM. The success rate of valuable data for the analysis was 100%. 

    KV4.3/KChIP2 - Dose-response curve of Flecanaide

    icon sp96   170922 KV4.3 Data SyncroPatch384PESyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing KV4.3/KChIP2 current traces in response to a voltage step protocol and the corresponing current-voltage relationship plot. Using whole cell mode in combination with multi-hole chips (4 holes per well), stably transfected cells were measured on the SyncroPatch 384PE. The IC50 value of flecanaide was determined as 28.3 µM which is in accordance to literature. The success rate of valuable data for the analysis was 100%. 

    CaV1.2 - Stable recording from frozen stock cells

    icon sp96   170922 CaV1.2 Data SyncroPatch384PESyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing hCaV1.2β2/α2δ1 current traces in response to a voltage step protocol and the corresponing current-voltage relationship plot. Measured on the SyncroPatch 384PE using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 100 %. The cells were used from a frozen cell stock (after induction) and recorded stably for more than 20 minutes. The IC50 value of Nifedipine was determined as 21 nM.

    KV1.5 - Dose response curve of 4-AP

    icon sp96   KV1.5 Data 3845PESyncroPatch 384PE data and applications:
    Cells were kindly provided by Charles River.

    Screenshots of the PatchControl 384 software showing a dose-response curve of 4-AP on KV1.5 stably transfected cells. Measured on the SyncroPatch 384PE using multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 100%. The IC50 value of 160 µM measured on the SyncroPatch 384PE corresponds well to literature (IC50 4-AP: 270 µM; Gutman et al., Pharmacological Reviews 57: 473-508, 2005). 

    P2X2/ P2X3 - Application of ATP

    P2X23 10uATPicon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) data and applications: 
    Cells were kindly supplied by Evotec AG, Hamburg, Germany

    Shown are three consecutive current responses of 1321 N1 cells expressing P2X2 / P2X3 receptors to 10 µM ATP. Cells were washed twice between compound applications (holding −80 mV). The data demonstrate the reproducability of the whole cell current responses.

    インタビュー

    Dr. Al George - Statement about the SyncroPatch 384PE

    icon sp96   “We are extraordinarily excited about installing the first SyncroPatch 384PE in an academic setting in North America. The enormous throughput, intuitive software and robust liquid handling capabilities along with superior seal quality, stability and high success rates convinced us to purchase the instrument. The SyncroPatch 384PE will enable us to perform detailed high throughput analysis of genetic variants in human ion channels at a previously unobtainable scale, and will form the cornerstone of a new HTS facility we are building. We also look forward to upgrading to 768 wells in the near future.“

    Dr. Al George
    Professor and Chair of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Dr. David Dalrymple - Statement about the SyncroPatch 384PE

    icon sp96   “As a leading ion channel contract research organization running one of the most comprehensive ranges of ion channel assays, SB Drug Discovery has been impressed with the flexibility and reliability of the SyncroPatch 384PE, enabling development of a range of varied and complex ion channel assay for both high throughput screening and hit-to-lead profiling purposes. The SyncroPatch has proven to be a crucial addition to SB’s ion channel capabilities and in partnership with expert advice from Nanion’s support team has enabled SB to advance its ion channel capabilities to the forefront of ion channel drug discovery research..“

    Dr. David Dalrymple
    Business Development Director at SB Drug Discovery

    ウェビナー&動画

    ウェビナー

    12.09.2018 | Webinar: CiPA study: Bridging ion channel and myocyte data

    180912 event image CiPAII Webinar

    Icon CE   CardioExcyte 96,   icon pl   Patchliner and   icon sp96   SyncroPatch 384PE Webinar

    Date: September 12, 4:00 PM CEST (10:00 AM EDT)

     Get up-to-date with the CiPA progress of the Myocyte and Ion Channel Work Goups:

    • CiPA myocyte phase II validation study results: cross-site comparison using the CardioExcyte 96
    • HTS Phase I study: an update on progress of the CiPA Ion Channel Work Stream using the SyncroPatch 384PE and Patchliner

    08.05.2018 | Webinar: HTS Sodium Ion Channel Assays on the SyncroPatch 384PE

    icon sp96   SyncroPatch 384PE

    Learn about Sodium Ion Channel Assays on the SyncroPatch 384PE. Our speakers will present assays on NaV1.1, NaV1.7, NaV1.8 and NaV1.9:

    • Biophysical and Pharmacological Characterization of Voltage-Gated Na Channels Involved in Pain Pathways.
    • Identifying NaV1.1  Enhancers to Restore Inhibitory Interneuron Function in Dravet Syndrome and Alzheimer’s Disease.

    03.11.2016 | External Webinar: Accelerating Ion Channel Characterization and New Drug Candidate Identification

    icon sp96   SyncroPatch 384PE

    This webinar will show high-throughput functional annotation of human ion channel variants associated with excitation disorders will be described along with use of the Syncropatch 384PE to measure subtype selective activation of KV7 potassium channels as well as inhibition of voltage gated sodium channels like NaV1.7, NaV1.1, and NaV1.5.
    Organisation: Icagen Inc.

    07.06.2016 | External Webinar: A new analysis capability to improve assessment of cardiac liability in high throughput electrophysiology

    icon sp96   SyncroPatch 384PE

    AstraZeneca has implemented the Nanion SyncroPatch 384PE electrophysiology platform. This webinar will show how AstraZeneca and Genedata developed a processing and analysis pipeline for the complex data, reading binary raw data directly from the instrument into Genedata Screener.
    Organisation: Genedata AG.

    28.07.2015 | Webinar: High Throughput and High Fidelity: Automated Patch Clamp in Screening and Research

    icon sp96   SyncroPatch 384PE and   icon pl   Patchliner 

    The webinar covers the use of the Patchliner and the SyncroPatch 384/768PE for characterization of ion channels and screening of ion channel active compounds.

    24.10.2013 | Webinar: SyncroPatch 384PE - the PatchEngine. Superior Ion Channel Drug Screening

    icon sp96   SyncroPatch 384PE

    The Webinar covers the introduction of the SyncroPatch 384PE and its features.

    07.03.2013 | Webinar: Top gear ion channel screening

    icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE)

    This Webinar covers the general setup of the and features of this automated patch clamp device.

    動画

    2018 - HTS Phase I study: an update on progress of the CiPA Ion Channel Work Stream using the SyncroPatch 384PE and Patchliner

    icon sp96   SyncroPatch 384PE,   icon pl   Patchliner and   Icon CE   CardioExcyte 96 Oral Presentation

    Presenter: 
    Tim Strassmaier, Nanion Technologies Inc. USA
    Source:
    Webinar: "CiPA study: Bridging ion channel and myocyte data", September 12, 2018

    2018 - Biophysical and Pharmacological Characterization of Voltage-Gated Sodium Channels Involved in Pain Pathways

    icon sp96   SyncroPatch 384PE Oral Presentation Video

    Presenter: 
    Dr. Markus Rapedius, Senior Scientist, Nanion Technologies

    ダウンロード:

    アプリケーションノート

    AMPA receptor (GluA2) - Activation, potentiation and inhibition of AMPA receptors on the SyncroPatch 384PE

    icon sp96   SyncroPatch 384PE application note:   logo pdf   (3.1 MB)
    Cells were kindly provided by SB Drug Discovery.

    ASIC3 - "Activation and Inhibition of human ASIC3 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note:   logo pdf   (2.2 MB)
    Cells were kindly provided by Millipore.  

    Cardiac Ion Channels - "High Throughput Screening of Cardiac Ion Channels"

    icon sp96   SyncroPatch 384PE   icon pl   Patchliner   Icon CE   CardioExcyte 96 application note   logo pdf   (2.3 MB)

    Cardiac Ion Channels - "Simultaneous Assessment of CiPA Stipulated Ion Channels on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.3 MB)
    Cells were kindly provided by Charles River.

    Cardiomyocytes - "Combining automated patch clamp, impedance and EFP of hiPSC-CMs"

    Icon CE   CardioExcyte 96   icon sp96   SyncroPatch 3984PE   icon pl   Patchliner Application Note 
    Cells kindly provided by Takara-Clonetech.

    CaV1.2 - "High Throughput Pharmacology of CaV1.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note:   logo pdf   (2.7 MB)
    Cells were kindly provided by SB Drug Discovery.  

    CaV1.2 - "Stability and Pharmacology of CaV1.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (5.3 MB)
    Cells were kidly provided by Charles River.

    CaV1.3 - "Characterization of CaV1.3 on Nanion's SyncroPatch 96"

    icon sp96   SyncroPatch 96 (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.5 MB)

    CaV3.2 - "High Throughput Pharmacology of CaV3.2 Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note:   logo pdf   (0.6 MB)
    Cells were kindly provided by Millipore.  

    CFTR - "Different modes of activation of CFTR recorded on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (5.7 MB)

    GABAA a1b3g2 - "Characterization of hGABAA α1β3γ2 on Nanion's SyncroPatch 96"

    icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.5 MB)
    Cells were kibndly provided by Millipore.

    GABAA a5b3g2 - "Characterization of hGABAA α5β3γ2 on Nanion's SyncroPatch 96"

    icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.5 MB)
    Cells were kindly provided by Millipore.

    hERG - "High Throughput Pharmacology of hERG Channels on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (0.6 MB)

    NaV1.5 - "High Throughput Pharmacology of NaV1.5 Channels on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.9 MB)
    Cells were kindly provided by Millipore.

    NaV1.7 - "Characterization of hNaV1.7 on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (0.7 MB)
    Cells were kindly provided by Anaxon.

    NaV1.7 - "Pharmacology on rNaV1.7 performed on Nanion‘s SyncroPatch 96"

    icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.6 MB)
    Cells were kindly provided by Millipore.

    NaV1.8 - "Characterization of rNaV1.8 (ND7-23) on Nanion's SyncroPatch 96"

    icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.7 MB)
    Cells were kindly provided by Millipore.

    NaV1.8 - "Stability and reproducibility of hNaV1.8 recordings on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.4 MB)
    Cells were kindly provided by Charles River.

    NMDA Receptors (NR1/NR2A & NR1/NR2B) - "Activation and Inhibition of human NMDA Channels on Nanion`s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (3.0 MB)
    Cells were kindly provided by Charles River.

    TMEM16A (ANO1) - "Internal perfusion of Ca2+ to activate TMEM16A/ANO1 on the SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (6.8 MB)
    Cells were kindly provided by SB Drug Discovery.

    TREK-1 - "Activation and inhibition of TREK-1 on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (6.0 MB)
    Cells were kindly provided by SB Drug Discovery.

    TRPA1 - "High Throughput Activation and Block of hTRPA1 on Nanion’s SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (0.6 MB)
    Cells were kindly provided by Millipore.

    TRPC5 - "Internal perfusion of Ca2+ to activate hTRPC5 on Nanion's SyncroPatch 384PE"

    icon sp96   SyncroPatch 384PE application note   logo pdf   (1.7 MB)
    Cells were kindly provided by Charles River.

    論文

    2018 - Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903

    icon sp96   SyncroPatch 384PE article in Bioorganic and Medicinal Chemistry Letters (2018)

    Authors:
    Sharma, S.H., Pablo J.L., Montesinos, M.S., Greka, A., Hopkins, C.R.

    2018 - Synthesis by native chemical ligation and characterization of the scorpion toxin AmmTx3

    icon sp96   SyncroPatch 384PE article in Bioorganic and Medicinal Chemistry Letters (2018)

    Authors:
    Zoukimian, C., Meudal, H., De Waard, S., Ait Ouares, K., Nicolas, S Canepari, M, Béroud, R, Landon, C., De Waard, M., Boturyn, D.

    2018 - High-Throughput Functional Evaluation of KCNQ1 Decrypts Variants of Unknown Significance

    icon sp96   SyncroPatch 384PE article in Circulation: Genomic and Precision Medicine (2018)

    Authors:
    Vanoye C.G., Desai R.R., Fabre K.L., Gallagher S.L., Potet F., DeKeyser J.M., Macaya D., Meiler J, Sanders C.R, and George Jr. A.L.

    2018 - Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment

    icon sp96   SyncroPatch 384PE article in European Journal of Pharmacology (2018)

    Authors:
    Asahi Y., Nomura F., Abe Y., Doi M., Sakakura T., Takasuna K., Yasuda K

    2018 - A Novel Gain-Of-Function Mutation Of Piezo1 Is Functionally Affirmed In Red Blood Cells By High-Throughput Patch Clamp

    icon sp96   SyncroPatch 384PE publication in Haematologica (2018)

    Authors:
    Rotordam G.M., Fermo E., Becker N., Barcellini W., Brüggemann A., Fertig N., Egée S., Rapedius M., Bianchi P., Kaestner L.

    2018 - Developing High-Throughput Assays to Analyze and Screen Electrophysiological Phenotypes

    icon sp96   SyncroPatch 384PE book chapter in Phenotypic Screening (2018)

    Authors:
    Pan J.Q., Baez-Nieto D., Allen A., Wang HR., Cottrell J.R.

    2018 - Multifocal atrial and ventricular premature contractions with an increased risk of dilated cardiomyopathy caused by a Nav1.5 gain-of-function mutation (G213D)

    icon sp96   SyncroPatch 384PE-related publication in International Journal of Cardiology (2018)

    Authors:
    Calloe K., Broendberg A.K., Christensen A.H., Pedersen L.N., Olesen M.S., de los Angeles Tejada M., Friis S., Thomsen M.B., Bundgaard H., Jensen H.K.

    2018 - NaV Channels: Assaying Biosynthesis, Trafficking, Function

    icon sp96   SyncroPatch 384PE article in The Surfaceome (2018)

    Authors:
    Tomaselli G.F., Farinelli F.

    2018 - An update on the advancing high-throughput screening techniques for patch clamp-based ion channel screens: implications for drug discovery

    icon sp96   SyncroPatch 384/768PE and   icon pl   Patchliner publication in Expert Opinion on Drug Discovery

    Authors: 
    Obergrussberger A., Goetze T.A., Brinkwirth N., Becker N., Friis S., Rapedius M., Haarmann C., Rinke-Weiß I., Stölzle-Feix S., Brüggemann A., George M., Fertig N.

    2018 - Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors

    icon sp96  SyncroPatch 768PE publication in PNAS

    Authors: 
    Chernov-Rogan T., Li T., Lu G., Verschoof H., Khakh K., Jones S.W., Beresini M.H., Liu C., Ortwine D.F., McKerrall S.J., Hackos D.H., Sutherlin D., Cohen C.J., and Chen J.

    2017 - Characterization of a KCNB1 variant associated with autism, intellectual disability, and epilepsy

    icon sp96  SyncroPatch 768PE publication in Neurology Genetics (2017)

    Authors: 
    Calhoun, J.D., Vanoye, C.G., Kok, F., George, A.L., Kearney, J.A.

    2017 - High-throughput electrophysiological assays for voltage gated ion channels using SyncroPatch 768PE

    icon sp96  SyncroPatch 768PE publication in PLoS One (2017)

    Authors: 
    Li T, Lu G, Chiang E.Y., Chernov-Rogan T., Grogan J.L., Chen J.

    2017 - Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions

    icon sp96  SyncroPatch 768PE publication in Nature Communications (2017)

    Authors: 
    Chiang E.Y., Li T., Jeet S., Peng I., Zhang J., Lee W. P., DeVoss J., Caplazi P., Chen J., Warming S., Hackos D.H., Mukund S., Koth C.M., Grogan J.L.

    2017 - Automated Patch Clamp Recordings of Human Stem Cell- Derived Cardiomyocytes.

    icon pl  Patchliner and   icon sp96   SyncroPatch 384PE book chapter in Stem Cell-Derived Models in Toxicology (2017)

    Authors: 
    Obergrussberger A., Haarmann C., Stölzle-Feix S., Becker N., OhtsukiA., Brüggemann A., George M., Fertig N.

    2016 - Use-dependent Block of Human Cardiac Sodium Channels by GS967

    icon sp96  SyncroPatch 384PE publication in Molecular Pharmacology (2016)

    Authors: 
    Potet F., Vanoye C.G., George Jr. A.L.

    2016 - pH-sensitive K+ channel TREK-1 is a novel target in pancreatic cancer

    icon sp96  SyncroPatch 384PE publication in Biochimica et Biophysica Acta (2016)

    Authors: 
    Sauter D.R.P., Sørensen C.E., Rapedius M., Brüggemann A., Novak I.

    2016 - Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module

    icon sp96  SyncroPatch 384PE publication in Journal of Lab Automation (2016)

    Authors: 
    Obergrussberger A., Brüggemann A., Goetze T.A., Rapedius M., Haarmann C., Rinke I., Becker N., Oka T., Ohtsuki A., Stengel T., Vogel M., Steindl J., Mueller M., Stiehler J., George M., Fertig N.

    2015 - Novel screening techniques for ion channel targeting drugs

    icon pl  Patchliner,   icon sp96   SyncroPatch 384PE and   Icon CE   CardioExcyte 96 publication in Channels (2015)

    Authors: 
    Obergrussberger A., Stölzle-Feix S., Becker N., Brüggemann A., Fertig N., Möller C.

    2015 - Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp

    icon sp96  SyncroPatch 384PE publication in BCM Pharmacology and Toxicology (2015) 

    Authors: 
    Haraguchi Y., Ohtsuki A., Oka T., Shimizu T.

    2014 - New strategies in ion channel screening for drug discovery: are there ways to improve its productivity?

    icon sp96  SyncroPatch 384PE publication in Journal of Laboratory Automation (2014)

    Authors: 
    Farre C., Fertig N.

    2014 - Early identification of hERG liability in drug discovery programs by automated patch clamp

    icon pl  Patchliner and   icon sp96   SyncroPatch 384PE publication in Frontiers in Pharmacology (2014)

    Authors: 
    Danker T., Moeller C.

    2012 - Natural and artificial ion channels for biosensing platforms

    icon pap   Port-a-Patch,   icon pl   Patchliner,   icon sp96   SyncroPatch 96 ((a predecessor model of SyncroPatch 384PE) and   icon vpp   Vesicle Prep Pro publication in Analytical and Bioanalytical Chemistry (2012)

    Authors: 
    Steller L., Kreir M., Salzer R.

    2012 - HTS techniques for patch clamp-based ion channel screening - economy and advances

    icon pap   Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Expert Opinion on Drug Discovery (2012)

    Authors: 
    Farre C. and Fertig N.

    2011 - State-of-the-art automated patch clamp devices: heat activation, action potentials, and high throughput in ion channel screening

    icon pap   Port-a-Patch,   icon pl  Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Frontiers in Pharmacology (2011)

    Authors: 
    Stoelzle S., Obergrussberger A., Brüggemann A., Haarmann C., George M., Kettenhofen R., Fertig N.

    2011 - Automated electrophysiology makes the pace for cardiac ion channel safety screening

    icon pl  Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE) publication in Frontiers in Pharmacology (2011)

    Authors: 
    Möller C., Witchel H.

    2010 - Renaissance of ion channel research and drug discovery by patch clamp automation

    icon pap  Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 96 (a predecessor model of SyncroPatch 384PE)  publication in Future Medical Chemistry (2010)

    Authors:
    Farre C. and Fertig N.

    製品カタログ

    SyncroPatch 384/768PE - Product Sheet

    icon sp96   SyncroPatch 384/768PE product sheet:   logo pdf   (0.8 MB)

    ポスター

    2018 - Expression and pharmacology of GluA2-containing AMPA receptors in cell lines and stem cell-derived neurons

    icon pap   Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 384PE poster, Europhysiology Meeting 2018  logo pdf   (0.9 MB)

    2018 - Combining electrophysiology and contractility recordings for more complete assessment of hiPSC-CMs

    icon sp96   SyncroPatch 384PE,   icon pl   Patchliner and   Icon CardioExcyte 96 simpel RGB   CardioExcyte 96 poster, Europhysiology Meeting 2018  logo pdf   (1.4 MB)

    2017 - Pharmacological Characterization of the NMDA A-B-C by Automated Patch Clamp

    icon sp96   SyncroPatch 384PE poster, BPS Meeting 2017  logo pdf   (4.9 MB)

    2017 - Cardiomyocytes in Voltage Clamp and Current Clamp by Automated Patch Clamp

    icon sp96   SyncroPatch 384PE and   icon pl   Patchliner poster, BPS Meeting 2017  logo pdf   (1.7 MB)

    2018 - Investigating pain pathways by inhibition of voltage-gated sodium channels

    icon sp96   SyncroPatch 384PE and   icon pl   Patchliner poster, FENS Meeting 2018  logo pdf   (2.5 MB)

    2017 - lnvestigation of the Ion Channels hTMEM16A/Ano1 and TRPC5 and their Modulation by Intracellular Calcium

    icon sp96   SyncroPatch 384PE poster, BPS Meeting 2017  logo pdf   (1.3 MB)

    2017 - Activation of CFTR channels in absence of internal fluoride using a highly parallel automated patch clamp system

    icon sp96   SyncroPatch 384PE poster, BPS Meeting 2017  logo pdf   (1.5 MB)

    2018 - ハイスループット自動パッチクランプ システムの進展:安全性薬理試験への応用

    icon sp96   SyncroPatch 384PE poster, JSPS Meeting 2018  logo pdf   (2.3 MB)

    2018 - Optogenetic technologies enable high throughput ion channel drug discovery and toxicity screening

    icon sp96   SyncroPatch 384PE and   Icon CE   CardioExcyte 96 poster, Biophysics Annual Meeting 2018  logo pdf   (1.3 MB)

    2016 - Next level toxicity screening: From single channel to overall cell behavior

    Icon Orbit Mini   Orbit mini,   Icon CE   CardioExcyte 96 and   icon sp96   SyncroPatch 384PE poster, Meeting of the French Society of Toxinology (SFET) 2015  logo pdf   (0.9 MB)

    2015 - Organellar Transporters and Ion Channels - How to access their electrophysiology by using the SURFE2R technology and Planar Patch Clamp

    Icon N1   SURFE²R N1 and   icon sp96   SyncroPatch 96 (a predecessor model of the SyncroPatch 384PE) and   icon pap   Port-a-Patch poster, GRC - Organellar Channels and Transporters 2015   logo pdf   (1.6 MB)

    2015 - The backstage pass to study your favorite TRP channel

    icon pap   Port-a-Patch and   icon pl   Patchliner and SyncroPatch 384PE and   icon sp96   SyncroPatch 384PE poster, TRP Meeting 2015   logo pdf   (2.2 MB)

    2015 - High Throughput Automated Patch Clamp of Ion Channels Important in Cardiac Safety and Drug Discovery

    icon sp96  SyncroPatch 384PE poster, Chantest Meeting 2015   logo pdf   (1.9 MB)

    2015 - Complementary automated patch clamp, extracellular field potential and impedance recordings of iPSCs: safety screening tool box for the future

    icon pl   Patchliner and   Icon CE   CardioExcyte 96 and   icon sp96   SyncroPatch 384PE poster,   SPS 2015   logo pdf   (2.7 MB)

    %MCEPASTEBIN%
    Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
    More information Ok